Telemetry Investments L.L.C. acquired a new position in shares of Corvus Pharmaceuticals Inc (NASDAQ:CRVS) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 135,123 shares of the company’s stock, valued at approximately $496,000.

Several other hedge funds have also recently modified their holdings of CRVS. Acadian Asset Management LLC grew its stake in shares of Corvus Pharmaceuticals by 59.2% during the 3rd quarter. Acadian Asset Management LLC now owns 34,229 shares of the company’s stock valued at $293,000 after buying an additional 12,735 shares during the period. BlackRock Inc. lifted its holdings in Corvus Pharmaceuticals by 7.8% in the 3rd quarter. BlackRock Inc. now owns 1,206,520 shares of the company’s stock worth $10,350,000 after buying an additional 87,013 shares in the last quarter. Hikari Power Ltd lifted its holdings in Corvus Pharmaceuticals by 305.1% in the 4th quarter. Hikari Power Ltd now owns 130,000 shares of the company’s stock worth $477,000 after buying an additional 97,910 shares in the last quarter. Trexquant Investment LP acquired a new stake in shares of Corvus Pharmaceuticals in the 3rd quarter valued at about $107,000. Finally, Credit Suisse AG acquired a new stake in shares of Corvus Pharmaceuticals in the 3rd quarter valued at about $194,000. 85.83% of the stock is currently owned by institutional investors.

Shares of NASDAQ:CRVS traded up $0.03 during midday trading on Friday, reaching $4.24. 34,534 shares of the company’s stock were exchanged, compared to its average volume of 100,658. Corvus Pharmaceuticals Inc has a 12 month low of $3.22 and a 12 month high of $13.91.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.10. On average, equities research analysts expect that Corvus Pharmaceuticals Inc will post -1.6 EPS for the current year.

In other Corvus Pharmaceuticals news, CEO Richard A. Md Miller acquired 10,000 shares of the business’s stock in a transaction dated Thursday, December 20th. The shares were acquired at an average price of $4.40 per share, with a total value of $44,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Leiv Lea acquired 24,700 shares of the business’s stock in a transaction dated Friday, December 21st. The stock was acquired at an average cost of $4.15 per share, for a total transaction of $102,505.00. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 74,700 shares of company stock valued at $278,105. 39.50% of the stock is owned by corporate insiders.

A number of equities research analysts recently weighed in on CRVS shares. ValuEngine downgraded shares of Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. Zacks Investment Research cut shares of Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, January 7th. Finally, Wedbush cut their target price on shares of Corvus Pharmaceuticals from $19.00 to $11.00 and set an “outperform” rating for the company in a research note on Wednesday. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $11.94.

ILLEGAL ACTIVITY WARNING: “Telemetry Investments L.L.C. Takes Position in Corvus Pharmaceuticals Inc (CRVS)” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://theolympiareport.com/2019/03/15/telemetry-investments-l-l-c-takes-position-in-corvus-pharmaceuticals-inc-crvs.html.

Corvus Pharmaceuticals Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.

Read More: Technical Analysis

Want to see what other hedge funds are holding CRVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corvus Pharmaceuticals Inc (NASDAQ:CRVS).

Institutional Ownership by Quarter for Corvus Pharmaceuticals (NASDAQ:CRVS)

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.